PERSONATHER
PERSONALIZED THERAPY

# A cell line to test the biological activity of the RASG12V oncogene

## The oncogenic role of RASG12V

The RAS oncogene is one of the most frequently mutated oncogenes in cancer cells. Many research teams are trying to develop therapies aimed at blocking its oncogenic functions.

## A cell line model to study the biological role of the RASG12V oncogene

Personather has developed a cell line that allows for the study of the RAS oncogene to happen. This line was devoid of another oncogene that is present in it without genetic modification. This was the EGFRvIII oncogene, which shows amplification.
Under these conditions, the introduction of the RASG12V oncogene causes EGFRvIII-deficient cells to regain the characteristics of cancer cells.
The results of studies describing this phenomenon have been included in publications.
The DKMGRASG12V line is therefore a model line to examine the impact of RASG12 on cell biology. It can also be used to study potential blockers of RAS oncogenes.
[Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells-EGFRvIII Appears as a Weak Oncogene - PubMed (nih.gov)]










PERSONATHER Ltd.
R&D Laboratory , Inwestycyjna 7 Street
95-050 Konstantynow Lodzki, Poland

phone/fax:
00 48 577 643 986
Piotr Rieske 00 48 504 643 986

e-mail:
terapiacelowana@gmail.com
piotr.rieske@personather.com